Biocompounding

1) Eisai and Biogen Report Positive Phase III Data for Anti-Amyloid Alzheimer's Drug Eisai and Biogen announced that the duo’s Alzheimer's drug, Lecanemab, slowed the rate of cognitive decline for early Alzheimer’s participants in the phase 3 clinical trial by 27% compared to a

1. Iveric plans FDA submission of data for geographic atrophy eye-drug following study success Iveric Bio announced positive phase 3 topline data from Zimura for geographical atrophy (GA). Zimura is a novel investigational complement C5 inhibitor. Overactivity of the complement system and the C5 protein are suspected to play a

1. FDA clears updated COVID-19 boosters from Pfizer, Moderna A long-awaited moment! On Wednesday, FDA approved a new version of Pfizer’s vaccine for adults and children over 12 years old and Moderna’s modified shot for adults who are 18 or older. Both vaccines are bivalent, meaning that they